Skip to main content
Erschienen in: Drug Safety 8/2009

01.08.2009 | Original Research Article

Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

A Retrospective Cohort Study of over 473 000 Patients Using the National Health Insurance Database in Taiwan

verfasst von: Fei-Yuan Hsiao, Weng-Foung Huang, Yu-Wen Wen, Pei-Fen Chen, Ken N. Kuo, Dr Yi-Wen Tsai

Erschienen in: Drug Safety | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and objective: Concern has been expressed over the cardiovascular risks associated with rosiglitazone and pioglitazone. This study investigates the association between oral antihyperglycaemics (rosiglitazone, pioglitazone, sulfonylureas and metformin) with myocardial infarction, congestive heart failure, angina pectoris, stroke and transient ischaemic attack.
Methods: We used Taiwan’s 2000–5 National Health Insurance database to conduct a population-based, retrospective cohort study of 473 483 newly diagnosed patients with type 2 diabetes mellitus. We classified study patients into five basic groups based on the agents they were prescribed during the study period: (i) rosiglitazone monotherapy; (ii) pioglitazone monotherapy; (iii) sulfonylurea-based therapy; (iv) metformin-based therapy; and (v) sulfonylurea and metformin-based therapy. Cox proportional hazards models were used to evaluate the association between the use of rosiglitazone or pioglitazone and the occurrence of cardiovascular events.
Results: Patients receiving rosiglitazone monotherapy were at higher risk for any cardiovascular event (hazard ratio [HR] 1.89; 95% CI 1.57, 2.28), myocardial infarction (HR 2.09; 95% CI 1.36, 3.24), angina pectoris (HR 1.79; 95% CI 1.39, 2.30) and transient ischaemic attack (HR 2.57; 95% CI 1.33, 4.96) than those receiving metformin monotherapy. Overall, add-on rosiglitazone and pioglitazone were associated with comparable cardiovascular risk. Based on our point estimates, pioglitazone as an add-on therapy was found to have a favourable, but nonsignificant, effect on outcome.
Conclusions: Our findings extend the evidence from current literature to a real-world setting and support data from clinical trials that the disadvantages or harm caused by thiazolidinediones, especially rosiglitazone, may outweigh their benefits in patients with type 2 diabetes.
Literatur
1.
Zurück zum Zitat Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373–405PubMedCrossRef Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373–405PubMedCrossRef
2.
Zurück zum Zitat Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71PubMedCrossRef Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71PubMedCrossRef
3.
Zurück zum Zitat Home PD, Pocock SJ, Beck-Nielsen H, et al., on behalf of the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28–38PubMedCrossRef Home PD, Pocock SJ, Beck-Nielsen H, et al., on behalf of the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28–38PubMedCrossRef
6.
Zurück zum Zitat Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population-based study. BMJ 2001; 322: 1389–93PubMedCrossRef Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population-based study. BMJ 2001; 322: 1389–93PubMedCrossRef
10.
Zurück zum Zitat Nesto RW, Bell D, Bonow RO, et al., on behalf of the American Heart Association, American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003; 108: 2941–8PubMedCrossRef Nesto RW, Bell D, Bonow RO, et al., on behalf of the American Heart Association, American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003; 108: 2941–8PubMedCrossRef
11.
Zurück zum Zitat Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129–36PubMedCrossRef Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129–36PubMedCrossRef
12.
Zurück zum Zitat Rajagopalan R, Rosenson RS, Fernandes AW, et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004; 26: 1400–10PubMedCrossRef Rajagopalan R, Rosenson RS, Fernandes AW, et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004; 26: 1400–10PubMedCrossRef
13.
Zurück zum Zitat Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22: 986–93PubMedCrossRef Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22: 986–93PubMedCrossRef
14.
Zurück zum Zitat Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Car 2005; 28: 20–6CrossRef Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Car 2005; 28: 20–6CrossRef
15.
Zurück zum Zitat Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–90PubMedCrossRef Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–90PubMedCrossRef
16.
Zurück zum Zitat Singh S, Loke YK, Fuberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189–95PubMedCrossRef Singh S, Loke YK, Fuberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189–95PubMedCrossRef
17.
Zurück zum Zitat Psaty BM, Furberg CD. The record of rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007; 357: 67–9PubMedCrossRef Psaty BM, Furberg CD. The record of rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007; 357: 67–9PubMedCrossRef
18.
Zurück zum Zitat Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180–8PubMedCrossRef Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180–8PubMedCrossRef
19.
Zurück zum Zitat Hernandez AV, Walker E, Ioannidis JP, et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J 2008; 156: 23–30PubMedCrossRef Hernandez AV, Walker E, Ioannidis JP, et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J 2008; 156: 23–30PubMedCrossRef
20.
Zurück zum Zitat Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 16 147: 578–81PubMed Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 16 147: 578–81PubMed
21.
Zurück zum Zitat Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634–43PubMedCrossRef Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634–43PubMedCrossRef
22.
Zurück zum Zitat Winkelmayer WC, Setoguchi S, Levin R, et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368–75PubMedCrossRef Winkelmayer WC, Setoguchi S, Levin R, et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368–75PubMedCrossRef
24.
Zurück zum Zitat Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16: 1065–71PubMedCrossRef Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16: 1065–71PubMedCrossRef
25.
Zurück zum Zitat Johannes CB, Koro CE, Quinn SG, et al. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16: 504–12PubMedCrossRef Johannes CB, Koro CE, Quinn SG, et al. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16: 504–12PubMedCrossRef
26.
Zurück zum Zitat McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711–25PubMedCrossRef McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711–25PubMedCrossRef
27.
Zurück zum Zitat Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070–80PubMedCrossRef Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070–80PubMedCrossRef
28.
Zurück zum Zitat Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05). iStudy. PROactive Investigators. J Am Coll Cardiol 2007; 49: 1772–80PubMedCrossRef Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05). iStudy. PROactive Investigators. J Am Coll Cardiol 2007; 49: 1772–80PubMedCrossRef
Metadaten
Titel
Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
A Retrospective Cohort Study of over 473 000 Patients Using the National Health Insurance Database in Taiwan
verfasst von
Fei-Yuan Hsiao
Weng-Foung Huang
Yu-Wen Wen
Pei-Fen Chen
Ken N. Kuo
Dr Yi-Wen Tsai
Publikationsdatum
01.08.2009
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 8/2009
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200932080-00006

Weitere Artikel der Ausgabe 8/2009

Drug Safety 8/2009 Zur Ausgabe

Correspondence

The Authors’ Reply